Invesaro

Stocks Health care TEVA

NYSE · Health care

Teva Pharmaceutical Industries Ltd (TEVA)

Teva Pharmaceutical Industries Ltd brought in $14.1B of revenue over the twelve months to June 30, 2026, down 15.2% from a year earlier. Operating cash flow minus capital spending left $1.1B of free cash flow in fiscal 2025. At June 30, 2026 it held $3.7B in cash against $4.5B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on July 29, 2026.

Free, no password. An email when TEVA files with the SEC.

Price
$39.23
+1.79% on the day · November 20, 2026
52-week range $24.34 to $44.57
Market cap
$45.7B
Revenue (last 12 months)
$14.1B
-15.2% year on year
P/E
32.4
on FY2025 diluted EPS

Key facts about Teva Pharmaceutical Industries Ltd

Net worth
Teva Pharmaceutical Industries Ltd has a market value (market cap) of $45.7B at the latest share price, and shareholders' equity of $7.8B on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Revenue and profit
In fiscal 2025 revenue was $17.3B (+4.3% year on year), with net income of $1.4B.
Cash flow
In fiscal 2025 operations brought in $1.6B of cash; after $501M of capital spending, free cash flow was $1.1B.
Latest report
The latest periodic report (quarterly report, 10-Q) was filed with the SEC on July 29, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
Next earnings report
Teva Pharmaceutical Industries Ltd's next report was expected around November 4, 2026 and is not on file with the SEC yet.

What Teva Pharmaceutical Industries Ltd does

Teva Pharmaceutical Industries develops, produces, and markets generic pharmaceuticals, active pharmaceutical ingredients, and specialty medicines. The company supplies prescription drugs, over-the-counter treatments, and sterile injectables to healthcare systems, pharmacies, and hospitals worldwide. Its shares trade on NYSE under the ticker TEVA.

Revenue and profit by year

Revenue
FY18: $18.3B $18.3B FY18FY19: $16.9B $16.9B FY19FY20: $16.7B $16.7B FY20FY21: $15.9B $15.9B FY21FY22: $14.9B $14.9B FY22FY23: $15.8B $15.8B FY23FY24: $16.5B $16.5B FY24FY25: $17.3B $17.3B FY25
Net income
FY18: -$2.2B -$2.2B FY18FY19: -$999M -$999M FY19FY20: -$4B -$4B FY20FY21: $417M $417M FY21FY22: -$2.4B -$2.4B FY22FY23: -$559M -$559M FY23FY24: -$1.6B -$1.6B FY24FY25: $1.4B $1.4B FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$17.3B$2.2B$1.4B$1.21$1.1B
2024$16.5B-$303M-$1.6B-$1.45$749M
2023$15.8B$433M-$559M-$0.50$842M
2022$14.9B-$2.2B-$2.4B-$2.20$1B
2021$15.9B$1.7B$417M$0.38$236M
2020$16.7B-$3.6B-$4B-$3.64$638M

Earnings: every quarter and the next report date

Full financial statements: income, balance sheet and cash flow

A report was expected around November 4, 2026 and is not on file yet.

Estimated from its filing rhythm: 52 weeks after its report of November 5, 2025. Not a date the company has announced. See the report calendar · Earnings, quarter by quarter

Where TEVA ranks in Health care

Revenue$17.3B
#33 of 751 in Health care · Top 4%
Revenue growth+4.3%
#359 of 532 in Health care · Bottom 33%
Net margin8.2%
#132 of 544 in Health care · Top 24%
Free cash flow margin6.7%
#157 of 490 in Health care · Top 32%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Dividends

Fiscal yearPer sharePaid outOf profit
2019$0.00n/an/a
2018$0.00$12Mn/a
2017$0.85$901Mn/a
2016$1.36$1.3B396%
2015$1.36$1.2Bn/a
2014$1.34$1.2Bn/a

Per share as declared (or paid, where only that is reported), adjusted for stock splits the company itself restated. Yield is the latest fiscal year's dividend over the current price.

Latest SEC filings

What Teva Pharmaceutical Industries Ltd has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. September 16, 2026
    Material agreement8-KTeva subsidiaries issued multiple series of euro and US dollar senior notes to fund debt redemptions and general corporate purposes.
  2. September 14, 2026
  3. September 14, 2026
  4. September 14, 2026
  5. September 11, 2026
  6. September 3, 2026
  7. September 3, 2026
  8. July 29, 2026
  9. July 29, 2026
    Quarterly report 10-Q · period to June 30, 2026Revenue fell 0.8% to $4.1B versus the same quarter last year; diluted EPS -$0.49 versus $0.24.
  10. July 29, 2026

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 22, 2026. Insider transactions on SEC

What is TEVA worth? A DCF from its reported cash flow

Insider trades

What the people running Teva Pharmaceutical Industries Ltd did with its shares, from the Form 4 filings they must send the SEC within two business days.

Insiders sold $14.6M worth of shares in the last 90 days and bought none on the open market.

Bought (open market)
$0
last 90 days
Sold
$14.6M
last 90 days
Net sold
374,942
$14.6M
DateInsiderWhatSharesPriceValueFiling
September 18, 2026 Mignone RobertoDirector Soldindirect 367,600 $39.06 $14.4M Form 4
September 18, 2026 Savage BrianInterim Chief Legal Officer Exercised options 4,503 $34.70 $156.3K Form 4
September 18, 2026 Savage BrianInterim Chief Legal Officer Sold 4,503 $38.69 $174.2K Form 4
September 18, 2026 Savage BrianInterim Chief Legal Officer Sold 2,525 $39.15 $98.8K Form 4
September 18, 2026 Savage BrianInterim Chief Legal Officer Sold 314 $38.70 $12.2K Form 4
August 21, 2026 Satchi-Fainaro RonitDirector Sold 415 $37.25 $15.5K Form 4
August 21, 2026 Weiss AmirChief Accounting Officer Sold 6,945 $37.61 $261.2K Form 4
August 21, 2026 Weiss AmirChief Accounting Officer Exercised options 2,500 $19.61 $49K Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns TEVA

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

HolderOf classSharesFiled
Harel Insurance Investments & Financial Services Ltd13G, passive 6.3% 72,325,555 February 9, 2026
Migdal Insurance & Financial Holdings Ltd13G, passive 5.37% 61,689,363 February 17, 2026
Menora Mivtachim Holdings Ltd13G, passive 5% 57,395,173 July 17, 2025
Phoenix Financial Ltd.13G, passive 5% 57,383,158 July 22, 2025

Latest filings below 5%: Fmr LLC 2.1% (November 5, 2025).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

19 insiders reported holding 4,900,622 shares in total, about $192.3M at the last price.

HolderSharesAs of
Elstein AmirDirector 2,118,455 June 5, 2026
Francis Richard DPresident and CEO 1,177,529 June 5, 2026
Barer Sol JDirector 448,011 June 5, 2026
Hughes Eric ASee "Remarks" 134,877 August 3, 2026
Lieberman Gerald MDirector 130,149 June 5, 2026
Crane Rosemary ADirector 127,739 June 5, 2026
Nisen PerryDirector 119,807 June 5, 2026
Mignone RobertoDirector 119,807 September 18, 2026
Satchi-Fainaro RonitDirector 111,986 August 21, 2026
Sabag MarkSee "Remarks" 80,760 May 1, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about TEVA

What does Teva Pharmaceutical Industries Ltd do?

Teva Pharmaceutical Industries develops, produces, and markets generic pharmaceuticals, active pharmaceutical ingredients, and specialty medicines. The company supplies prescription drugs, over-the-counter treatments, and sterile injectables to healthcare systems, pharmacies, and hospitals worldwide. Its shares trade on NYSE under the ticker TEVA.

What is Teva Pharmaceutical Industries Ltd's net worth?

Teva Pharmaceutical Industries Ltd has a market value (market cap) of $45.7B at the latest share price, and shareholders' equity of $7.8B on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

How much revenue does Teva Pharmaceutical Industries Ltd make?

Over the twelve months to June 30, 2026 Teva Pharmaceutical Industries Ltd reported revenue of $14.1B. That is 15.2% less than a year earlier.

When did Teva Pharmaceutical Industries Ltd last report?

Its most recent periodic report is the quarterly report (10-Q) filed on July 29, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 22, 2026.

When is Teva Pharmaceutical Industries Ltd's next earnings report?

Teva Pharmaceutical Industries Ltd's next report was expected around November 4, 2026 and is not on file with the SEC yet.

Similar companies

Compare TEVA with

Compare TEVA with any company

Follow TEVA

Get an email when Teva Pharmaceutical Industries Ltd files with the SEC: results, executive changes, material agreements and annual reports.

Free, no password. An email when TEVA files with the SEC.

Where the numbers come from

Financial figures are the values Teva Pharmaceutical Industries Ltd tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.